BioVersys AG开始第2阶段的试验 新的肺结核治疗, 结合甲醇-乙酰胺与标准药物。 BioVersys AG begins Phase 2 trial for new TB treatment combining alpibectir-ethionamide with standard drugs.

BioVersys AG在将白化病患者-乙酰胺与标准的肺结核药物相结合的第二阶段临床试验中招收并服用了第一个病人。 BioVersys AG has enrolled and dosed the first patient in a Phase 2 clinical trial combining alpibectir-ethionamide with standard TB drugs. 这项研究旨在评估这种新治疗在14天时期内的安全性和有效性。 The study aims to evaluate the safety and efficacy of this new treatment over a 14-day period. 这标志着首次在人类患者中测试这种药物组合。 This marks the first time this drug combination has been tested in human patients.